Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Seth A. Wander, Neil A. O’Brien, Lacey M. Litchfield, et al.
The Oncologist (2022) Vol. 27, Iss. 10, pp. 811-821
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Slower CDK4 and faster CDK2 activation in the cell cycle
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
Structure (2024) Vol. 32, Iss. 8, pp. 1269-1280.e2
Closed Access | Times Cited: 9
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
Francisco Cézar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 5, pp. 464-464
Open Access | Times Cited: 7
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Stephen Johnston, Anna Emde, Carlos H. Barrios, et al.
JNCI Cancer Spectrum (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 11
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, et al.
The Breast (2024) Vol. 75, pp. 103729-103729
Open Access | Times Cited: 4
Investigation of cytotoxic effect and action mechanism of a synthetic peptide derivative of rabbit cathelicidin against MDA-MB-231 breast cancer cell line
Marzieh Bashi, Hamid Madanchi, Bahman Yousefi
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Jamie O. Brett, Erica L. Mayer
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 6, pp. 594-610
Closed Access | Times Cited: 9
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
Paul Hanna, Ian A. Strohbehn, Daiana Moreno, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 9
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Inês Gomes, Catarina Abreu, Luís Costa, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4835-4835
Open Access | Times Cited: 8
Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer
Ahmad Awada, Sarfraz Ahmad
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5374-5383
Open Access | Times Cited: 2
Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System
Zicheng Yu, Mengying Guan, Xiaolan Liao
Clinical Drug Investigation (2024) Vol. 44, Iss. 10, pp. 789-798
Closed Access | Times Cited: 2
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
Leon Jonas Schönfeld, Christian Möhring, Raymond J. Strobel, et al.
Cancer Reports (2024) Vol. 7, Iss. 11
Open Access | Times Cited: 2
CELL CYCLE DYSREGULATION IN CANCER
Antonino Glaviano, Samarendra Kumar Singh, E. Hui Clarissa Lee, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 2, pp. 100030-100030
Closed Access | Times Cited: 2
Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
Yang Yuan, Shaohua Zhang, Tao Wang, et al.
Translational Breast Cancer Research (2023) Vol. 4, pp. 10-10
Open Access | Times Cited: 5
Autophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
Zhen Liu, Xiaoyang Wang, Han-Wei Wang, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation
Yanting Zhou, Xiandeng Li, Peifang Luo, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Molecular Subtypes of Breast Cancer and CDk Dysregulation
Manzoor Ahmad Mir, Ifshana Mohi Ud Din
(2023), pp. 133-148
Closed Access | Times Cited: 2
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Nino Balanchivadze, Nicholas J. Robert
Translational Breast Cancer Research (2023) Vol. 4, pp. 32-32
Open Access | Times Cited: 2
Palbociclib as an Antitumor Drug: A License to Kill
Agnieszka Łupicka‐Słowik, Federica Cossu, Marcin Sieńczyk
Molecules (2024) Vol. 29, Iss. 22, pp. 5334-5334
Open Access
Emerging predictive biomarkers in the management of bone and soft tissue sarcomas
Candace L. Haddox, Richard F. Riedel
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 5, pp. 495-502
Closed Access | Times Cited: 1
Clinical diagnostic and radiographic features of recurrent intracranial malignant triton tumor in an adult: illustrative case
Ajmain Chowdhury, Alex Belzer, Nahom Teferi, et al.
Journal of Neurosurgery Case Lessons (2023) Vol. 6, Iss. 8
Open Access | Times Cited: 1
ROS, Redox Regulation, and Anticancer Therapy
Mohinder Pal Bansal
(2023), pp. 311-409
Closed Access | Times Cited: 1
Autophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
Zhen Liu, X. Wang, Han-Wei Wang, et al.
Research Square (Research Square) (2023)
Open Access
Page 1 - Next Page

Scroll to top